Loading...
XKRX017180
Market cap41mUSD
Dec 26, Last price  
1,807.00KRW
1D
-0.93%
1Q
-18.42%
Jan 2017
-64.74%
IPO
-32.79%
Name

Myungmoon Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:017180 chart
P/E
—
P/S
0.36
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.36%
Rev. gr., 5y
2.83%
Revenues
169.57b
+11.46%
60,927,940,00077,390,430,00097,191,219,000105,183,289,000125,619,902,280100,538,968,880103,723,479,410105,420,701,980125,100,920,170142,179,739,050140,137,942,910147,498,532,160149,346,276,620127,852,855,900137,759,902,000152,134,940,500169,567,372,990
Net income
-4.52b
L
6,583,195,0004,863,329,0002,940,981,0003,067,853,0004,554,000,000-12,273,359,0001,025,971,000761,490,080-16,135,460,8406,745,899,0007,807,498,230988,268,550-20,832,841,850-27,753,013,560-6,804,256,8007,867,987,000-4,524,837,000
CFO
-5.18b
L
459,089,000-1,718,672,000-4,220,097,0002,870,640,000-1,415,963,4402,780,662,8102,003,532,500-36,233,890-5,504,596,3805,601,082,0508,023,816,12011,407,275,730-2,941,626,920-16,672,465,190854,995,9505,474,842,480-5,180,519,690
Dividend
Dec 27, 201795.424133 KRW/sh

Profile

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, fillers, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, oral disease products, antidiarrheal agents, digestive system products, cold drugs, calcium products, nasal sprays, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.
URL
http://www.mmpharm.co.kr/
IPO date
Jul 10, 2008
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
169,567,373
11.46%
152,134,940
10.43%
137,759,902
7.75%
Cost of revenue
149,661,146
123,077,424
123,020,385
Unusual Expense (Income)
NOPBT
19,906,227
29,057,517
14,739,517
NOPBT Margin
11.74%
19.10%
10.70%
Operating Taxes
92,609
(5,323,849)
206,138
Tax Rate
0.47%
1.40%
NOPAT
19,813,618
34,381,366
14,533,379
Net income
(4,524,837)
-157.51%
7,867,987
-215.63%
(6,804,257)
-75.48%
Dividends
Dividend yield
Proceeds from repurchase of equity
(674,929)
(123,000)
BB yield
0.88%
0.08%
Debt
Debt current
77,437,798
75,853,429
78,174,478
Long-term debt
14,427,586
9,560,300
8,203,865
Deferred revenue
270,672
782,672
Other long-term liabilities
18,377,034
13,265,846
13,856,998
Net debt
74,005,905
76,098,994
76,320,602
Cash flow
Cash from operating activities
(5,180,520)
5,474,842
854,996
CAPEX
(2,983,089)
(1,948,014)
(374,711)
Cash from investing activities
1,822,652
(4,932,292)
9,075,891
Cash from financing activities
6,454,906
(2,502,548)
(7,680,824)
FCF
15,324,776
31,747,563
32,840,997
Balance
Cash
11,664,446
9,984,249
10,516,636
Long term investments
6,195,033
(669,513)
(458,896)
Excess cash
9,381,110
1,707,989
3,169,746
Stockholders' equity
54,791,951
62,940,930
11,411,469
Invested Capital
188,232,653
189,012,763
180,859,636
ROIC
10.50%
18.59%
7.56%
ROCE
10.07%
14.96%
7.85%
EV
Common stock shares outstanding
33,679
33,806
33,806
Price
2,285.00
-20.38%
2,870.00
-39.32%
4,730.00
-34.94%
Market cap
76,956,622
-20.68%
97,022,617
-39.32%
159,901,387
-24.87%
EV
156,264,049
178,866,952
241,838,748
EBITDA
23,468,914
33,295,996
18,942,517
EV/EBITDA
6.66
5.37
12.77
Interest
5,137,471
3,734,552
3,041,555
Interest/NOPBT
25.81%
12.85%
20.64%